Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
7 December 2017
E-007570-17
Question for written answer
to the Commission
Rule 130
Nikos Androulakis (S&D)

 Subject:  Market for medicinal products in Greece
 Answer(s) 

According to representatives of pharmaceutical wholesalers in Greece, one pharmaceutical company announced that, as of 1 January 2018, it will only distribute medicinal products to wholesalers it has selected and not to any wholesaler who requests their distribution.

This decision places obstacles for many pharmaceutical wholesalers to operate as, pursuant to Greek law, pharmaceutical wholesalers carry out a public service task and must cover all pharmacies’ demands, especially in their geographical region.

At the same time, the selective distribution of medicinal products to specific pharmaceutical wholesalers only creates conditions of unequal treatment and distorts the market for medicinal products, even resulting in an increase in the product’s final price for medicines that do not require a prescription.

Given the above, can the Commission say:
Does this decision by a pharmaceutical company comply with European law and the goal to protect public health?
Is there a risk of creating an oligopoly? How is fair competition in the market for medicinal products ensured?
Original language of question: EL 
Last updated: 4 January 2018Legal notice